Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s traded shares stood at 1.27 million during the latest session, with the company’s beta value hitting 1.53. At the last check today, the stock’s price was $1.42, to imply a decrease of -25.65% or -$0.49 in intraday trading. The PRTK share’s 52-week high remains $3.65, putting it -157.04% down since that peak but still an impressive -11.97% since price per share fell to its 52-week low of $1.59. The company has a valuation of $108.05M, with an average of 0.27 million shares in intraday trading volume over the past 10 days and average of 302.87K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Paratek Pharmaceuticals Inc. (PRTK), translating to a mean rating of 1.30. Of 3 analyst(s) looking at the stock, 0 analyst(s) give PRTK a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.09.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) trade information
After registering a -25.65% downside in the latest session, Paratek Pharmaceuticals Inc. (PRTK) has traded red over the past five days. The stock hit a weekly high of 2.0000 this Wednesday, 03/15/23, dropping -25.65% in its intraday price action. The 5-day price performance for the stock is -15.97%, and -28.64% over 30 days. With these gigs, the year-to-date price performance is -24.06%. Short interest in Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) saw shorts transact 3.55 million shares and set a 18.98 days time to cover.
Analysts on Wall Street suggest a consensus price target of $19.67, implying an increase of 92.78% to the stock’s recent value. The extremes give us $9.00 and $30.00 for target low and target high price respectively. As such, PRTK has been trading -2012.68% off suggested target high and -533.8% from its likely low.
Paratek Pharmaceuticals Inc. (PRTK) estimates and forecasts
Looking at statistics comparing Paratek Pharmaceuticals Inc. share performance against respective industry, we note that the company has outperformed competitors. Paratek Pharmaceuticals Inc. (PRTK) shares are -41.07% down over the last 6 months, with its year-to-date growth rate higher than industry average at 16.39% against 9.40%. Revenue is forecast to grow 113.60% this quarter before jumping 108.60% for the next one. The rating firms project that company’s revenue will grow 13.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $63.45 million. Meanwhile, for the quarter ending Mar 2023, a total of 2 analyst(s) estimate revenue growth to $58.75 million.Earnings reports from the last fiscal year show that sales brought in $31.8 million and $24.86 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 99.50% before jumping 136.30% in the following quarter.
Paratek Pharmaceuticals Inc. has its next earnings report out on March 16. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Paratek Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s Major holders
Paratek Pharmaceuticals Inc. insiders hold 14.41% of total outstanding shares, with institutional holders owning 42.67% of the shares at 49.85% float percentage. In total, 42.67% institutions holds shares in the company, led by AIGH Capital Management LLC. As of Dec 30, 2022, the company held over 4.16 million shares (or 7.48% of shares), all amounting to roughly $5.86 million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 2.2 million shares, or about 3.96% of shares outstanding. As of the market price on Dec 30, 2022, these shares were worth $3.1 million.
We also have General American Investors Co and Bruce & Co., Inc. as the top two Mutual Funds with the largest holdings of the Paratek Pharmaceuticals Inc. (PRTK) shares. Going by data provided on Sep 29, 2022, General American Investors Co holds roughly 1.92 million shares. This is just over 3.45% of the total shares, with a market valuation of $2.7 million. Data from the same date shows that the other fund manager holds a little less at 1.43 million, or 2.57% of the shares, all valued at about 2.01 million.